SFPIA
SRPT icon

Stevens First Principles Investment Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Stevens First Principles Investment Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,000
Closed -$39K – 180
2015
Q4 		$39K Buy
+1,000
New +$32.4K 0.03% 114
2015
Q2 		– Sell
-300
Closed -$4K – 238
2015
Q1 		$4K Sell
300
-200
-40% -$2.67K ﹤0.01% 199
2014
Q4 		$7K Sell
500
-3,700
-88% -$62.7K ﹤0.01% 195
2014
Q3 		$89K Buy
4,200
+1,700
+68% +$38.4K 0.05% 125
2014
Q2 		$74K Buy
2,500
+1,500
+150% +$47.4K 0.04% 130
2014
Q1 		$24K Sell
1,000
-500
-33% -$12.7K 0.02% 156
2013
Q4 		$31K Buy
1,500
+500
+50% +$14.9K 0.02% 153
2013
Q3 		$47K Sell
1,000
-500
-33% -$19.3K 0.03% 141
2013
Q2 		$57K Buy
+1,500
New +$53.6K 0.04% 123

Other funds holding SRPT

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Stevens First Principles Investment Advisors's SRPT Position: Q1 2016 in Review

Stevens First Principles Investment Advisors sold out of Sarepta Therapeutics (SRPT) in Q1 2016, closing a stake of 1,000 shares — an estimated $39K sold.

Stevens First Principles Investment Advisors first reported a position in SRPT in Q2 2013 and held it in 9 quarters. The position peaked at $89K in Q3 2014. 132 funds tracked by Wall St. Rank hold SRPT as of Q1 2016.

  • Stevens First Principles Investment Advisors reported no remaining Sarepta Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Stevens First Principles Investment Advisors sold 1,000 Sarepta Therapeutics shares in Q1 2016, an estimated $39K.
  • Stevens First Principles Investment Advisors first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 9 quarters.
  • Stevens First Principles Investment Advisors's Sarepta Therapeutics position peaked at $89K in Q3 2014.
  • 132 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2016.

Based on Stevens First Principles Investment Advisors's 13F filing for Q1 2016, filed 13 May 2016.